RealFeedApp beta

D&D Pharmatech advances Phase 2 candidates

South Korean biopharmaceutical company D&D Pharmatech demonstrated a 62.5% resolution rate for metabolic dysfunction-associated steatohepatitis (MASH) with its new drug.

Field
drugs and trials
What they did
D&D Pharmatech developed a liver drug that resolved MASH (metabolic dysfunction-associated steatohepatitis) in 62.5% of patients.
Why it matters
This could be useful for patients with chronic metabolic diseases, as the drug is taken orally and aims to improve their condition.
#mash#biopharmaceutical#clinical trial

Read the original →